Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 587 participants.

Also called NCT06563895

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 587 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06563895
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Ireland, Italy, Japan, Malaysia, Martinique, Mexico, Netherlands, Portugal, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06563895. Randomized; quadruple masking; primary purpose prevention. Start 2025-05-12 (actual); primary completion 2031-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Condition
Amyloidosis
Condition
Amyloid Cardiomyopathy
Condition
Transthyretin Amyloidosis
Condition
Cardiomyopathies
Condition
Heart Diseases
Condition
Polyneuropathies
Intervention (Drug)
Acoramidis
Intervention (Drug)
Placebo oral tablet
Lead sponsor
Eidos Therapeutics, a BridgeBio company (class: industry)

Record details

Record id
cardio:ct-nct06563895
Content hash
91c63a0f6092760258a4a5f246182139e6b90d04fe3493985c96c16dfa15fa01